SecBot SecBot
SECBOTREPLAY Home › Report › SLDB

SLDB · Solid Biosciences reported Q1 2026 EPS of -$0.53, a 20.9% miss versus…

Solid Biosciences Inc. · PRESS-RELEASE filed May 12, 2026 at 16:08 ET

At the news

BEARISHIMPACT 6/10

PRESS-RELEASE filed May 12, 2026 at 16:08 ET

Solid Biosciences reported Q1 2026 EPS of -$0.53, a 20.9% miss versus the -$0.44 consensus, with net loss widening to $56.7M from $39.3M a year ago. The company highlighted Phase 3 Duchenne trial initiation and a strong cash position of $380.7M extending into H1 2028, but the earnings miss and rising R&D costs overshadow pipeline progress.

  • Q1 2026 EPS of -$0.53 missed consensus of -$0.44 by 20.9%
  • Net loss widened to $56.7M from $39.3M in Q1 2025
  • Cash, cash equivalents and securities totaled $380.7M as of March 31, 2026, up from $187.9M at year-end 2025
  • R&D expenses rose to $46.1M from $30.9M, driven by SGT-003 manufacturing and clinical costs

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access